Monday, December 11, 2017 -- (Reuters) - Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.
Monday, December 11, 2017 -- (Reuters) - Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.
Monday, December 11, 2017 -- New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
Monday, December 11, 2017 -- University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants.
Saturday, December 09, 2017 -- (MENAFN Editorial) NORTH CHICAGO, Ill., Dec. 9, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the ...
Saturday, December 09, 2017 -- (MENAFN Editorial) ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:), a leader in developing novel, controllable cellular immunotherapies for canc...
Tuesday, December 12, 2017 -- Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
Sunday, December 10, 2017 -- Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.
Sunday, December 10, 2017 -- Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.
Monday, December 11, 2017 -- Danelle James, MD, discusses the changing landscape at the ASH 2017 meeting in Atlanta.
Saturday, December 09, 2017 -- Alessandra Tedeschi, MD, discusses the latest findings on ibrutinib for treatment of chronic lymphocytic leukemia (CLL).
Tuesday, December 12, 2017 -- Gary Gordon, MD, PhD, discusses latest findings at the ASH 2017 meeting in Atlanta.
Saturday, December 09, 2017 -- Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
Tuesday, December 12, 2017 -- Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
Saturday, December 09, 2017 -- ATLANTA, Dec. 09, 2017 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced results from...
Sunday, December 10, 2017 -- – Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with...
Wednesday, December 13, 2017 -- New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) Freeze-dried, or lyophilized, formulation aims to improve supply management...
Wednesday, December 13, 2017 -- In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.
Thursday, December 14, 2017 -- For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.